294 related articles for article (PubMed ID: 11179328)
1. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.
Borrow R; Andrews N; Goldblatt D; Miller E
Infect Immun; 2001 Mar; 69(3):1568-73. PubMed ID: 11179328
[TBL] [Abstract][Full Text] [Related]
2. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England.
Andrews N; Borrow R; Miller E
Clin Diagn Lab Immunol; 2003 Sep; 10(5):780-6. PubMed ID: 12965904
[TBL] [Abstract][Full Text] [Related]
3. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
6. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children.
Vesikari T; Forsten A; Laudat F; Li P; Van Der Wielen M; Hezareh M; Perez JL; Webber C
Vaccine; 2020 May; 38(22):3902-3908. PubMed ID: 32284274
[TBL] [Abstract][Full Text] [Related]
7. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants.
Baxter R; Keshavan P; Welsch JA; Han L; Smolenov I
Hum Vaccin Immunother; 2016 May; 12(5):1300-10. PubMed ID: 26829877
[TBL] [Abstract][Full Text] [Related]
8. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.
Klein NP; Block SL; Essink B; Barbi S; Smolenov I; Keshavan P
Vaccine; 2019 Jul; 37(32):4460-4467. PubMed ID: 31279564
[TBL] [Abstract][Full Text] [Related]
9. Measurement of functional anti-meningococcal serogroup a activity using strain 3125 as the target strain for serum bactericidal assay.
Poolman JT; De Vleeschauwer I; Durant N; Devos N; Feron C; Lestrate P; Weynants V; Boutriau D
Clin Vaccine Immunol; 2011 Jul; 18(7):1108-17. PubMed ID: 21593240
[TBL] [Abstract][Full Text] [Related]
10. A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines.
Findlow J; Balmer P; Borrow R
Hum Vaccin Immunother; 2019; 15(10):2491-2500. PubMed ID: 30883271
[TBL] [Abstract][Full Text] [Related]
11. Understanding immunogenicity assessments for meningococcal serogroup B vaccines.
Balmer P; Beeslaar J; Findlow J; Srivastava A
Postgrad Med; 2020 Mar; 132(2):184-191. PubMed ID: 32124678
[TBL] [Abstract][Full Text] [Related]
12. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
[TBL] [Abstract][Full Text] [Related]
13. Persistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel.
Patel M; Romero-Steiner S; Broderick MP; Thomas CG; Plikaytis BD; Schmidt DS; Johnson SE; Milton AS; Carlone GM; Clark TA; Messonnier NE; Cohn AC; Faix DJ
Vaccine; 2014 Jun; 32(30):3805-9. PubMed ID: 24837781
[TBL] [Abstract][Full Text] [Related]
14. Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers.
Bash MC; Lynn F; Mocca B; Borrow R; Findlow H; Hassan-King M; Preziosi MP; Idoko O; Sow S; Kulkarni P; Laforce FM
Clin Vaccine Immunol; 2014 May; 21(5):755-61. PubMed ID: 24671551
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
16. Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines.
Serra L; Knuf M; Martinón-Torres F; Yi K; Findlow J
Hum Vaccin Immunother; 2021 Jul; 17(7):2205-2215. PubMed ID: 33606596
[TBL] [Abstract][Full Text] [Related]
17. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.
Gill CJ; Ram S; Welsch JA; Detora L; Anemona A
Vaccine; 2011 Dec; 30(1):29-34. PubMed ID: 22075087
[TBL] [Abstract][Full Text] [Related]
18. Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?
Findlow H; Borrow R
Hum Vaccin Immunother; 2015; 11(6):1501-6. PubMed ID: 25912095
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.
Auckland C; Gray S; Borrow R; Andrews N; Goldblatt D; Ramsay M; Miller E
J Infect Dis; 2006 Dec; 194(12):1745-52. PubMed ID: 17109348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
